FDG PET scan strategies and long-term outcomes after first-line therapy in Hodgkin's Disease

European Journal of Radiology

Volumn 70, Issue 3, 2009, Pages 499-506

  Poulou, Loukia S ^a   Karianakis, George ^b   Ziakas, Panayiotis D ^b  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b HYGEIA HOSPITAL   (Greece)

Author keywords

Computed tomography; Decision analysis; FDG PET; Hodgkin's disease; Restaging; Survival

Indexed keywords

COMPUTED TOMOGRAPHY; DECISION ANALYSIS; FDG PET; HODGKIN'S DISEASE; RESTAGING; SURVIVAL;

COMPUTERIZED TOMOGRAPHY; COSTS; DECISION MAKING; DECISION THEORY; GLUCOSE; POSITRON ANNIHILATION SPECTROSCOPY; SENSITIVITY ANALYSIS;

POSITRON EMISSION TOMOGRAPHY;

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE;

ALGORITHM; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CLINICAL DECISION MAKING; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; COST CONTROL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LONGITUDINAL STUDIES; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 67349155646     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.01.043     Document Type: Article

References (41)

1. Juweid M.E., Stroobants S., Hoekstra O.S., et al. Imaging subcommittee of international harmonization project in lymphoma. Use of positron emission tomography for response assessment of lymphoma:consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 25 (2007) 571-578
2. Weinstein M.C., and Fineberg H.V. Clinical decision analysis (1980), W.B. Saunders Company
3. Gobbi P.G., Levis A., Chisesi T., et al. Intergruppo Italiano Linfomi. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23 (2005) 9198-9207
4. Meyer R.M., et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23 (2005) 4634-4642
5. Straus D.J., Portlock C.S., Qin J., et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104 (2004) 3483-3489
6. Bonadonna G., Bonfante V., Viviani S., Di Russo A., Villani F., and Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 22 (2004) 2835-2841
7. Rueda Dominguez A., Marquez A., Guma J., et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 15 (2004) 1798-1804
8. le Maignan C., Desablens B., Delwail V., et al. Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. Blood 103 (2004) 58-66
9. Ferme C., Sebban C., Hennequin C., et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'etudes des lymphomes de l'Adulte H89 trial. Blood 95 (2000) 2246-2252
10. Lister T.A., Crowther D., Sutcliffe S.B., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7 (1989) 1630-1636
11. Isasi C.R., Lu P., and Blaufox M.D. A metaanalysis of 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104 (2005) 1066-1074
12. Bucerius J., Herkel C., Joe A.Y., et al. (18)F-FDG FDG PET and conventional imaging for assessment of Hodgkin's disease and non Hodgkin's lymphoma. An analysis of 193 patient studies. Nuklearmedizin 45 (2006) 105-110 [quiz N25-6]
13. Bjurberg M., Gustavsson A., Ohlsson T., and Brun E. FDG-FDG PET in the detection of residual disease and relapse in patients with Hodgkin's lymphoma. Experience from a Swedish centre. Acta Oncol 45 (2006) 743-749
14. Rigacci L., Castagnoli A., Dini C., et al. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results. Oncol Rep 14 (2005) 1209-1214
15. Panizo C., Perez-Salazar M., Bendandi M., et al. Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses. Leuk Lymphoma 45 (2004) 1829-1833
16. Jerusalem G., Beguin Y., Fassotte M.F., et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 14 (2003) 123-130
17. Naumann R., Vaic A., Beuthien-Baumann B., et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 115 (2001) 793-800
18. Spaepen K., Stroobants S., Dupont P., et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?. Br J Haematol 115 (2001) 272-278
19. Reece D.E., Barnett M.J., Shepherd J.D., et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 86 (1995) 451-456
20. Lazarus H.M., Rowlings P.A., Zhang M.J., et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 17 (1999) 534-545
21. Ferme C., Mounier N., Divine M., et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 20 (2002) 467-475
22. Josting A., Rueffer U., Franklin J., Sieber M., Diehl V., and Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 96 (2000) 1280-1286
23. Andre M., Henry-Amar M., Pico J.L., et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol 17 (1999) 222-229
24. Moskowitz C.H., Kewalramani T., Nimer S.D., et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 124 (2004) 645-652
25. Bonadonna G., Zucali R., Monfardini S., De Lena M., and Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36 (1975) 252-259
26. Canellos G.P., Anderson J.R., Propert K.J., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327 (1992) 1478-1484
27. Canellos G.P., Anderson J.R., Propert K.J., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 21 (2003) 607-614
28. Loeffler M., Brosteanu O., Hasenclever D., et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 16 (1998) 818-829
29. Aleman B.M., Raemaekers J.M., Tomisic R., et al., European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 67 (2007) 19-30
30. Perz J.B., Giles C., Szydlo R., et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant 39 (2007) 41-47
31. Castagna L., Magagnoli M., Balzarotti M., et al. Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study. Am J Hematol 82 (2007) 122-127
32. Wadehra N., Farag S., Bolwell B., et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant 12 (2006) 1343-1349
33. Majhail N.S., Weisdorf D.J., Defor T.E., et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 12 (2006) 1065-1072
34. Diehl V., and Behringer K. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HD)?. Cancer Invest 24 (2006) 713-717
35. Coughlin M., Deslauriers J., Beaulieu M., et al. Role of mediastinoscopy in pretreatment staging of patients with primary lung cancer. Ann Thorac Surg 40 (1985) 556-560
36. Rodriguez P., Santana N., Gamez P., et al. Mediastinoscopy in the diagnosis of mediastinal disease. An analysis of 181 explorations. Arch Bronconeumol 39 (2003) 29-34
37. Venuta F., Rendina E.A., Pescarmona E.O., et al. Ambulatory mediastinal biopsy for hematologic malignancies. Eur J Cardiothorac Surg 11 (1997) 218-221
38. Nogami M., Nakamoto Y., Sakamoto S., et al. Diagnostic performance of CT, FDG PET, side-by-side, and fused image interpretations for restaging of non-Hodgkin lymphoma. Ann Nucl Med 21 (2007) 189-196
39. Schaefer N.G., Taverna C., Strobel K., Wastl C., Kurrer M., and Hany T.F. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy-is biopsy of FDG-avid lesions still needed?. Radiology 244 (2007) 257-262
40. Josting A., Franklin J., May M., et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 20 (2002) 221-230
41. Provencio M., España P., Salas C., et al. Hodgkin's disease: unsuspected minimal activity in patients that die from causes other than tumoral progression. Leuk Lymphoma 42 (2001) 661-664